NCT05638503 Multi-center Study on New Cardiovascular Remodeling and Function Parameters in Hypertension
| NCT ID | NCT05638503 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Qilu Hospital of Shandong University |
| Condition | Hypertension |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,200 participants |
| Start Date | 2022-05-01 |
| Primary Completion | 2027-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,200 participants in total. It began in 2022-05-01 with a primary completion date of 2027-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators want to explore the relationship between different configurations of hypertension and the incidence of cardiovascular events by the guidelines reference range and EMINCA recommended reference range. Then the investigators want to enroll twenty research centers and 2200 hypertensions were planned to be collected and followed up in the 12th, 24th, 36th and 48th months after being enrolled in this study. Physical examination, ECG examination, laboratory examination, echocardiography and carotid ultrasound should be taken when baseline and follow-up. Echocardiographic measurement parameters were analyzed and the relationship between the echocardiographic measurement parameters and cardiovascular events and prognosis of hypertension.
Eligibility Criteria
Inclusion Criteria: 1. Age 30-75 years old; 2. No antihypertensive drugs were used and three blood pressure measurements were conducted on different days, with systolic blood pressure ≥ 140 mmHg (1 mmHg=0.133 kPa) and/or diastolic blood pressure ≥ 90 mmHg; or have a history of hypertension and are using antihypertensive drugs, even if the blood pressure is lower than 140/90 mmHg; 3. Left ventricular ejection fraction was normal (LVEF ≥ 0.5). 4. All patients agreed to participate in the experiment and signed the informed consent form. Exclusion Criteria: 1. Secondary hypertension caused by renal parenchymal diseases, renal vascular diseases, coarctation of aorta and endocrine system diseases; 2. Severe cardiovascular and cerebrovascular diseases; heart valve disease; persistent atrial fibrillation and severe arrhythmia; previously undergone cardiovascular disease surgery; 3. Abnormal liver function; abnormal renal function and diabetes; 4. Pregnant or breastfeeding women; 5. Expected survival time due to non-cardiovascular disease\<4 years; 6. Patients with poor echocardiographic image quality.
Contact & Investigator
Mei Zhang, PhD
PRINCIPAL INVESTIGATOR
Qilu Hospital of Shandong University
Frequently Asked Questions
Who can join the NCT05638503 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, up to 75 Years, studying Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05638503 currently recruiting?
Yes, NCT05638503 is actively recruiting participants. Contact the research team at daixh@vip.sina.com for enrollment information.
Where is the NCT05638503 trial being conducted?
This trial is being conducted at Jinan, China.
Who is sponsoring the NCT05638503 clinical trial?
NCT05638503 is sponsored by Qilu Hospital of Shandong University. The principal investigator is Mei Zhang, PhD at Qilu Hospital of Shandong University. The trial plans to enroll 2,200 participants.